Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin

Dobay, Maria Pamela; Lemonnier, François; Missiaglia, Edoardo; Bastard, Christian; Vallois, David; Jaı̈s, Jean-Philippe; Scourzic, Laurianne; Dupuy, Aurélie; Fataccioli, Virginie; Pujals, Anaïs; Parrens, Marie; Bras, Fabien Le; Rousset, Thérèse; Picquenot, Jean‐Michel; Martin, Nadine; Haı̈oun, Corinne; Delarue, Richard; Bernard, Olivier A.; Delorenzi, Mauro; Leval, Laurence de; Gaulard, Philippe

doi:10.3324/haematol.2016.158428

Cited by 173 publications

(201 citation statements)

References 15 publications

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…4,6 In addition, the tumor cells frequently express distinct markers that are expressed by follicular helper T (TFH) cells; in the Japanese multicenter study mentioned above, 3 CD279/PD-1 was positive in 62% of cases, CD10 in 30%, and CXCL13 in 91%. CD279/PD-1 was positive in 100%, CD10 in 89%, BCL6 in 91%, CXCL13 in 96%, and ICOS in 98% in a French-Swiss multicenter retrospective study, 7 while CD279/ PD-1 was positive in 95%, CD10 in 66%, and CXCL13 in 84% in the Comprehensive Oncology Measures of Peripheral T-cell Lymphoma (COMPLETE) study, a large prospective cohort study of newly diagnosed peripheral T-cell lymphoma (PTCL) patients in the USA. 8 Massive infiltration of accessory cells is another pathological feature of AITL.…”

Section: Pathology Of Aitlmentioning

confidence: 91%

“…7 It was also reported that none of five FTCL samples had IDH2 mutations. 7 These observations suggest that IDH2 mutations may confer the pathological features of AITL, which are not present in other T-cell lymphomas with the TFH phenotype.…”

mentioning

confidence: 97%

“…TET2 mutations were found in 64% of nodal PTCL with TFH phenotype, but in only 17% of PTCL without TFH phenotype. 7 Furthermore, three of four FTCL samples (75%) exhibited TET2 mutations. 7 The frequencies of DNMT3A mutations were 20%-30% in AITL, 7,13,27 comparable to those in all PTCL-NOS (27%-29%).…”

mentioning

confidence: 99%

“…7 Furthermore, three of four FTCL samples (75%) exhibited TET2 mutations. 7 The frequencies of DNMT3A mutations were 20%-30% in AITL, 7,13,27 comparable to those in all PTCL-NOS (27%-29%). 13,27 DNMT3A mutations were present in 10% of nodal PTCL with TFH phenotype and 4% of PTCL without TFH phenotype in a French-Swiss study.…”

mentioning

confidence: 99%

“…13,27 DNMT3A mutations were present in 10% of nodal PTCL with TFH phenotype and 4% of PTCL without TFH phenotype in a French-Swiss study. 7 In addition, one of four samples of FTCL had a DNMT3A mutation.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma

Fujisawa

Sakata‐Yanagimoto

2017

JCEH

View full text Add to dashboard Cite

Angioimmunoblastic T-cell lymphoma (AITL) has been classified as a subtype of mature T-cell neoplasms. The recent revision of the WHO classification proposed a new category of nodal T-cell lymphoma with follicular helper T (TFH)-cell phenotype, which was classified into three diseases: AITL, follicular T-cell lymphoma, and nodal peripheral T-cell lymphoma with TFH phenotype. These lymphomas are defined by the expression of TFH-related antigens, CD279/PD-1, CD10, BCL6, CXCL13, ICOS, SAP, and CXCR5. Although recurrent mutations in TET2, IDH2, DNMT3A, RHOA, and CD28, as well as gene fusions, such as ITK-SYK and CTLA4-CD28, were not diagnostic criteria, they may be considered as novel criteria in the near future. Notably, premalignant mutations, tumor-specific mutations, and mutations specific to tumor-infiltrating B cells were identified in AITL. Thus, multi-step and multi-lineage genetic events may lead to the development of AITL.

show abstract